Method for promoting exosome secretion of mesenchymal stem cells and culture medium thereof

By adding β-mercaptoethanol and anti-TGF-β single-domain antibodies to mesenchymal stem cell culture medium, the secretion efficiency of exosomes is improved, the problems of low exosome secretion efficiency and stability are solved, and more efficient is achieved exosome production and application.

CN119082012AInactive Publication Date: 2024-12-06GUANGZHOU JINGJIE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411441316.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-16
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The secretion efficiency of mesenchymal stem cell exosomes is low, which affects its application in clinical and large-scale production, and there are problems such as inconsistent quality, difficulty in maintaining stability and biological activity.

Method used

β-mercaptoethanol and anti-TGF-β single domain antibodies were used as exosome secretion promoters, and the secretion of exosomes was increased by adding in culture medium and the secretion of exosomes in cells was increased through signaling pathways.

Benefits of technology

It significantly improves the secretion of mesenchymal stem cell exosomes, ensures its reliability and stability in clinical and research, and is suitable for large-scale applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082012A_ABST
    Figure CN119082012A_ABST
Patent Text Reader

Abstract

The invention discloses a method for promoting mesenchymal stem cell exosome secretion. The method comprises the following steps: (1) culturing mesenchymal stem cells; (2) exosome secretion induction; (3) purifying the exosome; (4) examination of the exosome; during exosome secretion induction in the step (2), an exosome secretion promoter is added, and the exosome secretion promoter is any one or two of beta-mercaptoethanol and an anti-TGF-beta single domain antibody. The invention further discloses a mesenchymal stem cell exosome secretion induction culture medium, the culture medium comprises a basic culture medium and an exosome secretion accelerant, and the exosome secretion accelerant is any one or two of beta-mercaptoethanol and an anti-TGF-beta single domain antibody. The exosome secretion promoter has a good promotion effect on secretion of the exosome, the combined use effect of the exosome secretion promoter and the exosome secretion promoter is better, and the exosome secretion promoter is suitable for subsequent large-scale application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a method for promoting the secretion of exosomes from mesenchymal stem cells and a culture medium thereof. Background Art

[0002] Mesenchymal stem cell exosomes (MSC-derived exosomes) are a type of small vesicles secreted by mesenchymal stem cells, usually with a diameter of 30-150 nanometers. These exosomes contain biological molecules such as proteins, lipids, mRNA, and miRNA, and can affect a variety of biological processes by regulating intercellular communication. The main functions and applications of mesenchymal stem cell exosomes include the following aspects: (1) MSC exosomes can promote tissue repair and regeneration, and play a role in a variety of diseases and injuries by reducing inflammatory responses, inhibiting cell apoptosis, and promoting angiogenesis. (2) MSC exosomes have significant anti-inflammatory and immunomodulatory functions, which can reduce inflammatory responses and regulate the balance of the immune system. Therefore, they have potential in the treatment of autoimmune and inflammatory diseases. (3) In the study of nervous system damage and neurodegenerative diseases, MSC exosomes have shown the potential for neuroprotection and promoting neural regeneration. (4) Studies have found that MSC exosomes can inhibit the growth and metastasis of tumor cells in some cases, but their specific mechanisms and applications are still under further study.

[0003] At present, the secretion of exosomes from mesenchymal stem cells (MSCs) still faces several key difficulties and challenges, which limit its promotion in clinical application and large-scale production. The main difficulties include: (1) Due to the diverse sources of MSCs, the quality of MSCs from different donors or tissues may vary, which directly affects the consistency and reliability of MSCs as advanced therapeutic products. (2) The selection of raw materials may affect the proliferation, differentiation ability and paracrine activity of cells, thereby affecting the yield and function of exosomes. (3) In large-scale production, it is necessary to develop a suitable product formulation to maintain the stability and biological activity of exosomes. (4) MSCs exosomes exert immunomodulatory effects through multiple mechanisms, and the complexity of these mechanisms increases the difficulty of research and application. (5) Although MSCs exosomes show therapeutic potential, ensuring their safety and efficacy in clinical applications remains a challenge.

[0004] However, in the existing technology, the secretion efficiency of mesenchymal stem cell exosomes is low, which is difficult to meet clinical and research needs. Therefore, it is necessary to develop an effective method and culture medium that can significantly improve the secretion of exosomes based on existing methods. Summary of the invention

[0005] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide a method for promoting the secretion of exosomes from mesenchymal stem cells and a culture medium thereof.

[0006] Therefore, the present invention discloses a method for promoting the secretion of exosomes from mesenchymal stem cells, comprising the following steps:

[0007] (1) Culture of mesenchymal stem cells;

[0008] (2) induction of exosome secretion;

[0009] (3) purification of exosomes;

[0010] (4) Examination of exosomes;

[0011] In the step (2) of inducing exosome secretion, an exosome secretion promoter is added, wherein the exosome secretion promoter is any one or both of β-mercaptoethanol and anti-TGF-β single domain antibody.

[0012] Preferably, the concentration of β-mercaptoethanol used in the present invention is 50 mM.

[0013] Preferably, the anti-TGF-β single domain antibody of the present invention is used at a concentration of 50 ng / ml.

[0014] Preferably, the amino acid sequence of the TGF-β protein single-domain antibody VNAR of the present invention is as shown in SEQ ID NO.1.

[0015] Preferably, the codon-optimized TGF-β protein single-domain antibody VNAR nucleotide sequence of the present invention is as shown in SEQ ID NO.2.

[0016] In another aspect, the present invention further discloses a mesenchymal stem cell exosome secretion induction medium, the medium comprising a basal medium and an exosome secretion promoter, the exosome secretion promoter being any one or both of β-mercaptoethanol and an anti-TGF-β single domain antibody.

[0017] Preferably, the basal culture medium of the present invention is serum-free DMEM culture medium.

[0018] Preferably, the concentration of β-mercaptoethanol used in the present invention is 50 mM.

[0019] Preferably, the anti-TGF-β single domain antibody of the present invention is used at a concentration of 50 ng / ml.

[0020] On the other hand, the present invention also discloses a use of the mesenchymal stem cell exosome secretion induction medium in the preparation of mesenchymal stem cell exosomes.

[0021] Exosome secretion enhancers have a good promoting effect on the secretion of exosomes, and the combined effect of the two is better, which is suitable for subsequent large-scale applications.

[0022] Appropriate concentrations of β-mercaptoethanol can increase the secretion of MSC exosomes, possibly by regulating intracellular signaling pathways such as NF-κB, HIF-1α or other redox-related signaling molecules. This provides a new idea for regulating the secretion of cellular exosomes by chemical means.

[0023] TGF-β is a multifunctional cytokine that can activate multiple cell signaling pathways and affect cell behavior by binding to its receptor; antibodies that block TGF-β signals may induce MSCs to secrete more exosomes through a feedback mechanism. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Exosome TEM detection results.

[0025] Figure 2 The results of SDS-PAGE detection of TGF-β protein single domain antibody. M is a marker and 1 is a TGF-β protein single domain antibody. DETAILED DESCRIPTION

[0026] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0027] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. The culture medium used for the isolation and culture of human mesenchymal stem cells was purchased from Merck. Unless otherwise specified, the reagents and materials used in the following examples were commercially available.

[0028] Example 1: Cultivation of mesenchymal stem cells

[0029] 1.1 Rapidly thaw the frozen ADSCs in a 37°C water bath, add 5 ml of DMEM medium containing 10% FBS, mix well, centrifuge at 800 rpm for 5 minutes, discard the supernatant, resuspend with 5 ml of DMEM medium containing 10% FBS, and transfer to a 25 cm 2 Place in a culture flask at 37°C with 5% CO 2 The cells were cultured in an incubator and cell passage was performed when the cells grew to a confluence of about 80%.

[0030] 1.2 Discard the culture medium, wash the cells twice with PBS, add 2 ml of 0.25% trypsin, and place in a 37°C incubator for digestion for 2 to 3 minutes. After the cells are digested, add 3 ml of DMEM culture medium containing 10% FBS to resuspend them, mix well, centrifuge at 800 rpm for 5 minutes, discard the supernatant, resuspend with an appropriate amount of DMEM culture medium containing 10% FBS, and gently blow the cells to disperse them. Subculture the cells at a ratio of 1:3 to 1:5 and place them at 37°C with 5% CO 2 Culture in an incubator until use.

[0031] Example 2: Induction of exosome secretion

[0032] 2.1 When the cell confluence in Example 1 reaches 70-80%, serum-free DMEM medium is used, and the cells are cultured for another 24 hours, and the cell culture supernatant is collected and recorded as cell culture supernatant 1.

[0033] 2.2 When the cell confluence in Example 1 reaches 70-80%, serum-free DMEM medium is used, and an exosome secretion promoter is added to the medium. The exosome secretion promoter has a final concentration of 50 mM β-mercaptoethanol. The cells are cultured for another 24 hours, and the cell culture supernatant is collected and recorded as cell culture supernatant 2.

[0034] 2.3 When the cell confluence in Example 1 reaches 70-80%, serum-free DMEM medium is used, and an exosome secretion promoter is added to the medium. The exosome secretion promoter is a single domain antibody against TGF-β with a final concentration of 50 ng / ml. The cells are cultured for another 24 hours, and the cell culture supernatant is collected and recorded as cell culture supernatant 3.

[0035] 2.4 When the cell confluence in Example 1 reaches 70-80%, serum-free DMEM medium is used, and an exosome secretion promoter is added to the medium. The exosome secretion promoter includes a final concentration of 50 mM β-mercaptoethanol and a final concentration of 50 ng / ml of an anti-TGF-β single domain antibody. The cells are cultured for another 24 hours, and the cell culture supernatant is collected and recorded as cell culture supernatant 4.

[0036] Example 3: Purification of exosomes

[0037] 3.1 Take the same volume of cell culture supernatant 1 to cell culture supernatant 4 prepared in Example 2, centrifuge at 1000 rpm for 10 minutes to remove cell debris. After the supernatant is filtered through a 0.22 μm filter membrane, transfer it to a 100KD ultrafiltration tube and centrifuge it at 4000 rpm at 4°C for 30 minutes to obtain a concentrated solution containing exosomes, which is recorded as concentrated solution 1 to concentrated solution 4.

[0038] 3.2 Transfer the concentrates 1 to 4 to ultracentrifuge tubes respectively, and centrifuge at 100,000 g for 70 minutes at 4°C. Carefully discard the supernatant, resuspend the precipitate with an appropriate amount of the same volume of PBS, and centrifuge at 100,000 g for 70 minutes. Carefully discard the supernatant, resuspend the precipitate with an appropriate amount of the same volume of PBS, and then centrifuge at 100,000 g for 70 minutes. Carefully discard the supernatant, resuspend the precipitate with an appropriate amount of the same volume of PBS, which is the collected exosomes, recorded as exosomes 1 to exosomes 4, and stored at -80°C for future use.

[0039] Example 4: Examination of exosomes

[0040] 4.1 The samples of exosomes 1 to 4 prepared in Example 3 were dropped onto the copper grid respectively, and after drying, they were negatively stained with phosphotungstic acid. The morphology and size of the exosomes were observed under a transmission electron microscope. Figure 1 As shown, exosomes 1 to 4 prepared in the present invention all have typical morphological characteristics and a double-layer membrane structure, and the particle size ranges from 50 to 150 nm, and is mainly concentrated around 100 nm.

[0041] 4.2 According to the instructions, the particle size and concentration of the exosome suspension were determined using the NTA instrument. The results showed that the average particle size of exosomes 1 to exosomes 4 was 100 nm, and the particle size range was 50 nm to 150 nm. This result is consistent with the typical particle size range of exosomes (30-150 nm). The particle concentrations of exosomes 1 to exosomes 4 were 1.2×10^10particles / mL, 2.4×10^10particles / mL, 2.3×10^10particles / mL, and 4.3×10^10particles / mL, respectively, which indicates that the exosome secretion promoter has a good promoting effect on the secretion of exosomes, and the combination of the two has a better effect, which is suitable for subsequent large-scale applications.

[0042] 4.3 Flow cytometry was performed on exosomes using commercial antibodies. The results showed that exosomes 1 to 4 all expressed CD63, CD81 and CD9 proteins, indicating that exosomes 1 to 4 prepared by this method all met the basic characteristics of exosomes. The detection method is briefly described as follows:

[0043] (1) Dilute 20 μL of exosomes 1 to 4 to 60 μL respectively, take 30 μL of diluted exosomes 1 to 4 and add 20 μL of fluorescent-labeled antibodies (CD63, CD9, CD81) respectively, mix well, and incubate at 37°C in the dark for 30 min. (2) Add 1 mL of pre-cooled PBS, select an ultraspeed rotor, and ultracentrifuge at 4°C, 110,000 g for 70 min. (3) Carefully remove the supernatant, add 1 mL of pre-cooled PBS, select an ultraspeed rotor, and ultracentrifuge at 4°C, 110,000 g for 70 min again. (4) Carefully remove the supernatant and resuspend with 50 μL of pre-cooled 1× PBS. (5) Use standard samples to perform instrument performance test before loading exosome samples. Note that gradient dilution is required to avoid clogging of the sample injection needle. (6) After the sample is tested, the protein index results of the NanoFCM instrument can be obtained.

[0044] Example 5: Preparation of single domain antibodies against TGF-β

[0045] 5.1. Recombinant human TGF-β protein (Nanjing Oukai Biotechnology, P1230) was diluted to 100 μg / ml with shark saline. For the first immunization, the diluted antigen was mixed with Freund's complete adjuvant and emulsified, and immunization was performed by intraperitoneal injection, with 0.1 ml for immunization. Subsequently, Freund's incomplete adjuvant was mixed with the diluted antigen and emulsified, and immunization was performed by intraperitoneal injection, with 0.1 ml for immunization. A total of 3 immunizations were performed, with an interval of 2 weeks.

[0046] 5.2. Take the shark serum after immunization for transcriptome sequencing to analyze the antibody production in the shark, and extract the shark spleen and lymphocyte RNA for RT-PCR to obtain a high-throughput database containing only shark VNAR. Compare the obtained high-throughput sequencing results with the high-throughput database of VNAR, and screen the sequences that are contained in both databases and have a high content. The VNAR sequence obtained in combination with the screening results is shown in SEQ ID NO.1, which is a single-domain antibody of TGF-β protein.

[0047] 5.3. Codon optimization was performed on the TGF-β protein single domain antibody, and the optimized nucleotide was subcloned into the NcoI and XhoI sites of pET28a, and 6His was added to the C-terminus to facilitate purification, thereby obtaining pET28a-VNAR. The codon-optimized nucleotide sequence is shown in SEQ ID NO.2.

[0048] 5.4. Transform the pET28a-VNAR plasmid into BL21 (DE3) competent cells, spread on LB agar plates containing kanamycin, and culture at 36-37°C, inverted for 16-20 hours. Pick a single colony from the plate, inoculate it into 3 ml of LB medium containing kanamycin, and culture it at 36-37°C, 220-240r / min with shaking until the OD600nm value reaches 0.4-0.6. Harvest part of the bacterial solution and add sterile glycerol to a final concentration of 25% for storage.

[0049] 5.5. After plating the preserved pET28a-VNAR strain and picking a single colony for culture, add it to the LB liquid culture medium containing kanamycin resistance with a final concentration of 5μg / mL at a ratio of 1:100, and culture it at 37℃, 220rpm for activation, and culture it at 37℃, 220rpm for 4h. Then add IPTG with a final concentration of 0.5mM at a ratio of 1:1000, and culture it at 37℃ for 4h. Collect the bacteria at 12000rpm for 5min, resuspend it with PBS and centrifuge it again. After washing, add 2mL Lysis Buffer to resuspend the bacteria and perform ultrasonic disruption on ice. After the disruption is completed, centrifuge at 12000rpm for 5min, take the supernatant directly, purify it with a nickel column and dialyze it for liquid exchange, and then filter and sterilize it through a 0.22μm low protein adsorption filter membrane to obtain a single domain antibody of TGF-β protein. The content of the purified TGF-β protein single domain antibody was 1.58 mg / ml by BCA detection, and the SDS-PAGE detection results were as follows Figure 2 As shown, the expression level after purification was about 315 mg / L.

[0050] Comparing the activities of the TGF-β protein single domain antibody and the TGF-β protein monoclonal antibody (ab215715), it was found that the activity of the TGF-β protein single domain antibody of the present invention is better than that of the TGF-β protein monoclonal antibody.

[0051] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A method for promoting exosome secretion from mesenchymal stem cells, It is characterized in that The method comprises the following steps: (1) Culture of mesenchymal stem cells; (2) induction of exosome secretion; (3) purification of exosomes; (4) Examination of exosomes; In the step (2) of inducing exosome secretion, an exosome secretion promoter is added, wherein the exosome secretion promoter is any one or both of β-mercaptoethanol and anti-TGF-β single domain antibody.

2. The method according to claim 1, It is characterized in that The concentration of the β-mercaptoethanol used is 50 mM.

3. The method according to claim 1, It is characterized in that The anti-TGF-β single domain antibody was used at a concentration of 50 ng / ml.

4. The method according to claim 1, It is characterized in that The amino acid sequence of the TGF-β protein single domain antibody VNAR is shown in SEQ ID NO.

1.

5. The method according to claim 1, It is characterized in that The codon-optimized TGF-β protein single-domain antibody VNAR nucleotide sequence is shown in SEQ ID NO.

2.

6. A mesenchymal stem cell exosome secretion induction medium, It is characterized in that The culture medium comprises a basal culture medium and an exosome secretion promoter, wherein the exosome secretion promoter is any one or both of β-mercaptoethanol and an anti-TGF-β single domain antibody.

7. The culture medium according to claim 6, It is characterized in that The basic culture medium is serum-free DMEM culture medium.

8. The culture medium according to claim 6, It is characterized in that The concentration of the β-mercaptoethanol used is 50 mM.

9. The culture medium according to claim 6, It is characterized in that The anti-TGF-β single domain antibody was used at a concentration of 50 ng / ml.

10. Use of the mesenchymal stem cell exosome secretion induction medium as claimed in claim 6 in the preparation of mesenchymal stem cell exosomes.